Bendamustine

Bendamustine

Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	US FDA: Treanda
Pregnancy category	US: D (Evidence of risk)
Routes of administration	Intravenous
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name 4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid
PubChem CID	65628
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H21Cl2N3O2
Molar mass	358.262 g/mol

WikiDoc Resources for Bendamustine
Articles
Most recent articles on Bendamustine Most cited articles on Bendamustine Review articles on Bendamustine Articles on Bendamustine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bendamustine Images of Bendamustine Photos of Bendamustine Podcasts & MP3s on Bendamustine Videos on Bendamustine
Evidence Based Medicine
Cochrane Collaboration on Bendamustine Bandolier on Bendamustine TRIP on Bendamustine
Clinical Trials
Ongoing Trials on Bendamustine at Clinical Trials.gov Trial results on Bendamustine Clinical Trials on Bendamustine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bendamustine NICE Guidance on Bendamustine NHS PRODIGY Guidance FDA on Bendamustine CDC on Bendamustine
Books
Books on Bendamustine
News
Bendamustine in the news Be alerted to news on Bendamustine News trends on Bendamustine
Commentary
Blogs on Bendamustine
Definitions
Definitions of Bendamustine
Patient Resources / Community
Patient resources on Bendamustine Discussion groups on Bendamustine Patient Handouts on Bendamustine Directions to Hospitals Treating Bendamustine Risk calculators and risk factors for Bendamustine
Healthcare Provider Resources
Symptoms of Bendamustine Causes & Risk Factors for Bendamustine Diagnostic studies for Bendamustine Treatment of Bendamustine
Continuing Medical Education (CME)
CME Programs on Bendamustine
International
Bendamustine en Espanol Bendamustine en Francais
Business
Bendamustine in the Marketplace Patents on Bendamustine
Experimental / Informatics
List of terms related to Bendamustine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Bendamustine (INN, tradenames Ribomustin and Treanda) is a substance in the treatment of cancer. It belongs to the family of drugs called alkylating agents. It is also called SDX-105.

History

Bendamustine received its first marketing approval in Germany, which is marketed under the tradename Ribomustin, by Astellas Pharma GmbH's licensee, Mundipharma International Corporation Limited, which it is indicated as a single-agent or in combination with other anti-cancer agents for indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and market bendamustine HCl in Japan and selected Asia Pacific Rim countries.

On March 20, 2008, Cephalon received approval from the United States Food and Drug Administration to market bendamustine in the US, where it is sold under the tradename Treanda. Bendamustine is the first drug approved for patients with CLL in the US since 2001.